Myelodysplastic Syndromes, An Issue of Hematology/Oncology Clinics of North America, 1st Edition
Author :
Benjamin L. Ebert
Major strides have been made in the treatment and understanding of Myelodysplasia. The United States Food and Drug Administration (FDA) has approved three new drugs for the treatment of MDS; new disease genes have been discovered; major insights hav ...view more
Major strides have been made in the treatment and understanding of Myelodysplasia. The United States Food and Drug Administration (FDA) has approved three new drugs for the treatment of MDS; new disease genes have been discovered; major insights have been made into the biology of the disorder; and animal models of MDS have been developed. The articles in this issue illustrate the rapid progress in MDS research, from molecular pathophysiology to improved therapies. Insights into the biology of MDS, the development of model systems to study MDS, and the application of new technologies with unprecedented power to interrogate the cancer genome promise to increase the rate of discovery, transforming our understanding of MDS and leading to improvements in the treatment this disease.
Major strides have been made in the treatment and understanding of Myelodysplasia. The United States Food and Drug Administration (FDA) has approved three new drugs for the treatment of MDS; new disease genes have been discovered; major insights have been made into the biology of the disorder; and animal models of MDS have been developed. The articles in this issue illustrate the rapid progress in MDS research, from molecular pathophysiology to improved therapies. Insights into the biology of MDS, the development of model systems to study MDS, and the application of new technologies with unprecedented power to interrogate the cancer genome promise to increase the rate of discovery, transforming our understanding of MDS and leading to improvements in the treatment this disease.
https://www.us.elsevierhealth.com/myelodysplastic-syndromes-an-issue-of-hematologyoncology-clinics-of-north-america-9781437722031.html6302Myelodysplastic Syndromes, An Issue of Hematology/Oncology Clinics of North Americahttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9781437722031.jpg98.9998.99USDInStock/Medicine/Oncology/Clinics/Clinics6943887253525504113841826925145120Major strides have been made in the treatment and understanding of Myelodysplasia. The United States Food and Drug Administration (FDA) has approved three new drugs for the treatment of MDS; new disease genes have been discovered; major insights have been made into the biology of the disorder; and animal models of MDS have been developed. The articles in this issue illustrate the rapid progress in MDS research, from molecular pathophysiology to improved therapies. Insights into the biology of MDS, the development of model systems to study MDS, and the application of new technologies with unprecedented power to interrogate the cancer genome promise to increase the rate of discovery, transforming our understanding of MDS and leading to improvements in the treatment this disease. Major strides have been made in the treatment and understanding of Myelodysplasia. The United States Food and Drug Administration (FDA) has approved three new drugs for the treatment of MDS; new disease genes have been discovered; major insights have been made into the biology of the disorder; and animal models of MDS have been developed. The articles in this issue illustrate the rapid progress in MDS research, from molecular pathophysiology to improved therapies. Insights into the biology of MDS, the development of model systems to study MDS, and the application of new technologies with unprecedented power to interrogate the cancer genome promise to increase the rate of discovery, transforming our understanding of MDS and leading to improvements in the treatment this disease.00add-to-cart97814377220312011 and earlierProfessionalBy Benjamin L. Ebert, MD, PhD20101Book152w x 229h (6.00" x 9.00")Saunders0Apr 21, 2010IN STOCK - This may take up to 5 business days to shipBy <STRONG>Benjamin L. Ebert</STRONG>, MD, PhDClinicsClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
